On October 26, 2026, Lycia Therapeutics announced it had closed its upsized initial public offering.
The company sold 20,286,000 shares at $18 per share, including 2,646,000 shares bought through the underwriters’ full exercise of their additional-share option.
The offering generated approximately $365.1 million in gross proceeds, before underwriting discounts, commissions, and other expenses. All shares were issued by Lycia.
Lycia began trading on the Nasdaq Global Select Market on October 23, 2026, under the ticker LYCA.
Sources:
Lycia Shares Fall Nearly 10% After Hours Following $365.1 Mln IPO Closing
Two grants give director Jane Henderson 57,666 and 20,000 options at Lycia Therapeutics (LYCA).
Lycia Therapeutics closes ~$365M IPO with full option
Lycia Therapeutics IPO Closes at $365.1 Million, LYCA
Lycia Therapeutics closes $365 million upsized IPO By Investing.com
Lycia Therapeutics closes $365 million upsized IPO By Investing.com
Lycia leaps onto Nasdaq with upsized $318M IPO as Windward breezes toward listing
Lycia Therapeutics宣布完成扩大规模的首次公开发行及承销商超额配售选择权的全额行使
Lycia Shares Fall Nearly 10% After Hours Following ...
Lycia Therapeutics News | Markets Insider
Lycia Therapeutics, Inc. (LYCA) Stock Price, News, Quote ...